A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-09-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD)
of the amivantamab and cetrelimab combination therapy in participants with non-small cell
lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor
effect of the combination at the selected RP2CD in participants with NSCLC characterized by
epidermal growth factor receptor (EGFR) exon19del or exon 21 leucine 858 to arginine
substitution (L858R) mutations, who have progressed on or after prior standard of care
therapy with a 3rd generation tyrosine kinase inhibitor (TKI) and platinum-based
chemotherapy, in the Phase 2 (expansion).